Literature DB >> 18454791

Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?

Matthew R Smith1, A James O'Malley, Nancy L Keating.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18454791      PMCID： PMC3047398          DOI： 10.1111/j.1464-410X.2008.07707.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  18 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.

Authors:  L M Eri; P Urdal; A G Bechensteen
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

3.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Authors:  Alfredo Berruti; Luigi Dogliotti; Carlo Terrone; Stefania Cerutti; Giancarlo Isaia; Roberto Tarabuzzi; Giuseppe Reimondo; Mauro Mari; Paola Ardissone; Stefano De Luca; Giuseppe Fasolis; Dario Fontana; Salvatore Rocca Rossetti; Alberto Angeli
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

4.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.

Authors:  J C Smith; S Bennett; L M Evans; H G Kynaston; M Parmar; M D Mason; J R Cockcroft; M F Scanlon; J S Davies
Journal:  J Clin Endocrinol Metab       Date:  2001-09       Impact factor: 5.958

5.  Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer.

Authors:  J A Tayek; D Heber; L O Byerley; B Steiner; J Rajfer; R S Swerdloff
Journal:  Metabolism       Date:  1990-12       Impact factor: 8.694

Review 6.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

7.  Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.

Authors:  M Pyörälä; H Miettinen; M Laakso; K Pyörälä
Journal:  Circulation       Date:  1998-08-04       Impact factor: 29.690

8.  Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

Authors:  Matthew R Smith; Hang Lee; Francis McGovern; Mary Anne Fallon; Melissa Goode; Anthony L Zietman; Joel S Finkelstein
Journal:  Cancer       Date:  2008-05-15       Impact factor: 6.860

9.  Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

Authors:  Frances Dockery; Christopher J Bulpitt; Sanjiv Agarwal; Mandy Donaldson; Chakravarthi Rajkumar
Journal:  Clin Sci (Lond)       Date:  2003-02       Impact factor: 6.124

10.  Hyperinsulinemia as an independent risk factor for ischemic heart disease.

Authors:  J P Després; B Lamarche; P Mauriège; B Cantin; G R Dagenais; S Moorjani; P J Lupien
Journal:  N Engl J Med       Date:  1996-04-11       Impact factor: 91.245
View more
  7 in total

1.  Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies.

Authors:  A Zapatero; C González San Segundo; A Boladeras; A Gómez Caamaño; J López Torrecilla; X Maldonado
Journal:  Clin Transl Oncol       Date:  2014-09-03       Impact factor: 3.405

2.  Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Authors:  Nancy L Keating; A James O'Malley; Stephen J Freedland; Matthew R Smith
Journal:  J Natl Cancer Inst       Date:  2009-12-07       Impact factor: 13.506

Review 3.  Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Authors:  Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

4.  Considerations for Transgender People With Diabetes.

Authors:  Joy Moverley; Sarah Loebner; Brent Carmona; David Vuu
Journal:  Clin Diabetes       Date:  2021-10

Review 5.  Mortality, cardiovascular risk, and androgen deprivation therapy for prostate cancer: A systematic review with direct and network meta-analyses of randomized controlled trials and observational studies.

Authors:  Lucie-Marie Scailteux; Florian Naudet; Quentin Alimi; Sébastien Vincendeau; Emmanuel Oger
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

6.  Attenuation of Metabolic Syndrome by EPA/DHA Ethyl Esters in Testosterone-Deficient Obese Rats.

Authors:  Nikhil S Bhandarkar; Senthil Arun Kumar; Jarad Martin; Lindsay Brown; Sunil K Panchal
Journal:  Mar Drugs       Date:  2018-05-24       Impact factor: 5.118

Review 7.  Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.

Authors:  Wai-Kit Ma; Darren Ming-Chun Poon; Chi-Kwok Chan; Tim-Wai Chan; Foon-Yiu Cheung; Lap-Yin Ho; Eric Ka-Chai Lee; Angus Kwong-Chuen Leung; Simon Yiu-Lam Leung; Hing-Shing So; Po-Chor Tam; Philip Wai-Kay Kwong
Journal:  BJU Int       Date:  2019-02-05       Impact factor: 5.588
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.